Kornimate/medical-research-clean huggingface dataset:
measured hypocretin levels and recovery after hip surgery

Conditions: Osteoarthritis, Hip

Summary: a specific group of neurons in the brain produces hypocretin, a peptide which has been established as an important regulator of sleep and wakefulness. activation of these neurons (increased hypocretin) stabilizes wakefulness; impairing or blocking these neurons (decreased hypocretin) promotes sleep. evidence suggests that these neurons may be involved in the hypnotic properties of several anesthetics, and play a role in the induction and emergence from anesthesia. in humans there is a considerable inter-individual variability in hypocretin levels. this study aims to investigate how hypocretin levels affect the anesthetic care and recovery of patients undergoing elective hip surgery.


Eligibility criteria:
inclusion criteria:- adult (18 years of age or older) * male or female * scheduled for elective total hip arthroplasty at the stanford orthopedic clinic. * comprehend spoken and written english exclusion criteria:- asa physical status \> iii (patients with severe systemic disease) * diagnosed psychiatric disease (except mild depression) * any diagnoses cns disease or dementia * history of stroke * history of untreated thyroid disease * difficulty in airway management (ventilation and/or intubation) * body mass index (bmi) \> 35 kg/m2
to evaluate the role of lung ultrasonography for detection of atlelectasis in robot assisted laproscopic pelvic sugeries

Conditions: to Detect the Incidence of Atelectasis

Summary: pre op ultrasound with chest auscultation and arterial blood gas, after extubation ultrasound with chest auscultation and blood gas, 12hrs chest auscultation with ultasaound, 24 hrs chest auscultation and ultrasound to see atelectasis

pre op ultrasound with chest auscultation and arterial blood gas, after extubation ultrasound with chest auscultation and blood gas, 12hrs chest auscultation with ultasaound, 24 hrs chest auscultation and ultrasound to see atelectasis inclusion criteria: age 18 to 70 yrs age asa i and ii robot assisted pelvic surgeries in steep trendelenburg position exclusion criteria: cardiac disese severe obstructive and restrictive disease upper airways infection asaiii and iv

Eligibility criteria:
inclusion criteria: * asa iand ii age 18-70 yrs robot assisted pelvis surgeries exclusion criteria: * asa ii and iv cardiac and lung disease
induction therapy with serplulimab combined with chemotherapy for unresectable stage iii non-small cell lung cancer

Conditions: Unresectable Stage III Non-small-cell Lung Cancer

Summary: for unresectable stage iii (8th tnm) non-small cell lung cancer, chemoradiotherpay plus immunotherapy is recommended by pacific trial. however, it is unclear whether induction chemoimmunotherapy followed by surgery or radiotherapy can provide good survival for this population. this prospective observational study aims to investigate the efficacy and safety of the therapeutic regimen of chemoimmunotherapy plus surgery/radiotherapy.


Eligibility criteria:
inclusion criteria: 1. the patient shall sign the informed consent form. 2. aged 18 ≥ years. 3. histological or cytological diagnosis of unresectable nsclc by needle biopsy, and stage iii (8th tnm) confirmed by imageological examinations (ct, pet-ct or ebus). 4. eastern cooperative oncology group (ecog) performance-status score of 0 or 1. 5. life expectancy is at least 12 weeks. 6. at least 1 measurable lesion according to recist 1.1. 7. patients with good function of other main organs (liver, kidney, blood system, etc.) 8. patients with normal lung function can tolerate surgery; 9. without systematic metastasis (including m1a, m1b and m1c); 10. fertile female patients must voluntarily use effective contraceptives not less than 120 days after chemotherapy or the last dose of serplulimab (whichever is later) during the study period, and urine or serum pregnancy test results within 7 days prior to enrollment are negative. 11. unsterilized male patients must voluntarily use effective contraception during the study period not less than 120 days after chemotherapy or the last dose of serplulimab (whichever is later). exclusion criteria: 1. participants who have received any systemic anti-cancer treatment for thymic epithelial tumor, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment; 2. participants with any unstable systemic disease (including active infection, uncontrolled hypertension), unstable angina pectoris, angina pectoris starting in the last three months, congestive heart failure (\&gt;= nyha) grade ii), myocardial infarction (6 months before admission), severe arrhythmia requiring drug treatment, liver, kidney or metabolic diseases; 3. with activate or suspectable autoimmune disease, or autoimmune paracancer syndrome requiring systemic treatment; 4. participants who are allergic to the test drug or any auxiliary materials; 5. participants with interstitial lung disease currently; 6. participants with active hepatitis b, hepatitis c or hiv; 7. pregnant or lactating women; 8. participants suffering from nervous system diseases or mental diseases that cannot cooperate; 9. participated in another therapeutic clinical study; 10. other factors that researchers think it is not suitable for enrollment.

Keywords: unresectable stage iii non-small cell lung cancer chemoimmunotherapy
assessing an oral janus kinase inhibitor, azd4205 as monotherapy in patients who have ptcl (jackpot8)

Conditions: Relapsed or Refractory Peripheral T Cell Lymphoma

Summary: this is a multinational, non-randomized, open-label, phase 1/2 clinical study to evaluate the safety, tolerability and anti-tumor efficacy of azd4205 as monotherapy in patients with peripheral t cell lymphoma (ptcl), who have relapsed from or are refractory/intolerant to standard systemic treatment. phase 1 part: around 20\~40 patients will be subsequently enrolled into 2 different dose ascending cohorts. additional 10\~20 patients may be enrolled to further explore a selected dose defined by dose escalation cohorts. phase 2 part: after the recommended phase 2 dose (rp2d) is defined, a phase 2 single-arm open-label pivotal study will be conducted to assess anti-tumor efficacy and safety of azd4205 at rp2d in patients with refractory or relapsed ptcl.


Eligibility criteria:
inclusion criteria: 1. obtained written informed consent 2. patients must have histologically confirmed peripheral t-cell lymphoma according to the 2016 revision of the world health organization classiﬁcation of lymphoid neoplasms. tumor samples are required for central pathology review to confirm the diagnosis. 3. patients must have measurable disease according to the lugano criteria. 4. patients should be transplant-ineligible upon their entry into this study, and must have relapsed after or been refractory/intolerant to ≥ 1 (but not \> 3) prior systemic therapy(ies) for ptcl. 5. adequate bone marrow reserve and organ system functions. exclusion criteria: 1. any unsolved toxicity \> common terminology criteria for adverse events (ctcae) grade 1 from previous anti-cancer therapy (except alopecia). 2. active infections, active or latent tuberculosis. 3. patients with severely decreased lung function. 4. history of heart failure or qt interval prolongation. 5. central nervous system (cns) or leptomeningeal lymphoma. 6. history of treatment with janus kinase (jak) or signal transducer and activator of transcription 3 (stat3) inhibitor. 7. patient has undergone an allogeneic stem cell transplant. patient had autologous stem cell transplant within 6 months.
proximal risk for suicide in adolescents

Conditions: Suicide; Mental Health Issue

Summary: the central hypothesis is that biometric data can continuously monitor and allow for early identification/intervention of escalating suicidal symptoms. the rationale is that improved outpatient monitoring through wearable technology can create a more objective platform to provide the ability to identify a worsening condition and utilize patient-specific just-in-time therapeutics developed with mental health providers for suicidal adolescents.

suicide rates have exponentially increased, and it is now the 2nd leading cause of death in adolescence, accounting for over 1.2 million annual emergency department (ed) visits. after an ed visit or attempt, up to 20% of adolescents will have a second attempt within 12 months, and almost half will have a repeat ed visit. this proposal's overall objectives are to investigate physiologic parameters and biometric data from wearable technology that is temporally related to suicidal behavior and develop a personalized, predictive tool that can improve outpatient identification of adolescent patients with suicidality before a crisis develops requiring an ed visit. the central hypothesis is that biometric data can continuously monitor and allow for early identification/intervention of escalating suicidal symptoms. the rationale is that improved outpatient monitoring through wearable technology can create a more objective platform to provide the ability to identify a worsening condition and utilize patient-specific just-in-time therapeutics developed with mental health providers for suicidal adolescents. to attain the overall objectives, i will pursue the following specific aims: (i) to evaluate whether hrv, combined with patient-specific risk factors, can be used to detect dynamic changes in suicide severity among a prospective cohort of acutely suicidal adolescents, (ii) to utilize machine learning to determine whether there is a temporal relationship/signature in the raw ppg signal before or immediately after changes in suicide severity reporting combined with patient-specific risk factors to develop a prediction tool for suicidality risk. these aims will be accomplished in three years through a prospective observational study enrolling acutely suicidal adolescents in the ed and an inpatient psychiatric unit. ultimately, such knowledge can offer unique opportunities for early detection, just-in-time interventions, and support over 1.2 million suicidal adolescents presenting to eds nationally.

Eligibility criteria:
inclusion criteria: * subjects aged 13-17 years * presenting to the ed or inpatient psychiatric unit with a chief complaint of acute suicidality or attempt. exclusion criteria: * acutely agitated patients per the treating physician * adolescents who are not medically cleared from a suicide attempt * no legally authorized representative available to provide consent * parental report of significant developmental delay or autism diagnosis * prisoners * non-english speaking.

Keywords: adolescent emergency
spineology clinical outcomes trial: an ide investigation

Conditions: Lumbar Degenerative Disc Disease

Summary: this study evaluated the safety and effectiveness of the spineology interbody fusion system (sifs) in an instrumented interbody lumbar fusion in subjects presenting with symptomatic single-level lumbar degenerative disc disease.

this regulated prospective, multi-center, institutional review board (irb) approved single-arm performance goal clinical investigation was conducted at 10 centers with 102 subjects being enrolled and treated. subjects were actively evaluated from pre-op to 24-months postoperative. based on enrollment duration, some subjects were remotely assessed through self-administered surveys at 36- and/or 48-months. the primary endpoint, assessed at 24-months postoperative, is a composite score that includes pain, function, fusion and safety assessments.

Eligibility criteria:
inclusion criteria: * skeletally mature; * confirmed symptomatic single-level lumbar degenerative disc disease (ddd) between l2 and s1; * minimum low back visual analog scale (vas) pain score of 40mm; * minimum oswestry disability index (odi) score of 40; * received at least 6-months of conservative care; and * willing and able to comply with protocol evaluations and provide informed consent. exclusion criteria: * previous fusion or total disc replacement at the index level; * greater than grade i spondylolisthesis; * has symptomatic multi-level lumbar ddd; * active systemic infection or infection at the local surgical site; * active or suspected malignancy; * body mass index of greater than or equal to 40; * significant metabolic bone disease; * taking medication known to interfere with bone healing; * has a current substance abuse disorder; * has a somatoform, dissociative, eating or psychotic disorder; * waddell signs of inorganic behavior; * current tobacco user; * is a prisoner; * if female, pregnant or contemplating pregnancy during follow-up period; or * enrolled in a concurrent clinical investigation that may confound the findings of the current investigation
peer support for women with heart disease: women@heart

Conditions: Coronary Heart Disease; Women's Health

Summary: women with heart disease are more likely to die or suffer another cardiac event or stroke within 5 years of an index event compared to men. they are also more likely to suffer depression and report lower quality of life. cardiac rehabilitation programs have been designed to address these issues, but most women do not attend. women indicate they have a greater need to talk about their experiences with heart disease and seek social support to help them cope. peer support, the assistance provided by other women with a similar illness experience, may be one way to enhance social support for women with heart disease and help them improve their psychosocial well-being. the investigators have developed a peer support program called women@heart (w@h). the program is led by trained peer leaders (women who themselves have made a successful recovery from a heart event). a pilot test of the program showed promising results. the investigators now need to conduct a more rigorous evaluation of the program. the main objective of this project is to determine if the w@h program helps women to improve their psychosocial well-being compared to being on a waiting list to participate in the program. it will also examine the effect of the program on: health behaviours (tobacco smoking, physical activity, sedentary behaviour, fruit and vegetable consumption, and medication adherence); coronary risk factors; and clinical outcomes (re-hospitalization, health care system use, death).


Eligibility criteria:
inclusion criteria: 1. women who have been hospitalized at uohi in the past year with stable chd, including: ami; stable angina with corroborating evidence of chd; recent cabg; or percutaneous coronary intervention (to allow examination of mechanisms linking the intervention and psychosocial well-being with health and healthcare outcomes); 2. women ≥ 18 years of age (the age of consent in ontario); 3. women able to read and understand english or french; 4. women who reside in ontario and are eligible for ontario health insurance plan (to permit linkage with administrative data housed at the institute for clinical evaluative sciences \[ices\]); 5. women available to participate over the next 6 months (the intervention and data collection takes place over this time frame -- reducing the probability of missing data); 6. women able to provide informed consent. exclusion criteria: 1. women who have been hospitalized primarily for valve replacement or repair, hf, pulmonary hypertension, endocarditis or pericarditis (to reduce heterogeneity and avoid confounding when examining mechanisms linking the intervention and psychosocial well-being with health and healthcare outcomes); 2. women who, in the opinion of the uohi clinical psychologist, manifest psychiatric illness or cognitive impairment that would preclude participation in w@h (i.e. they are unable to benefit from the intervention, to prevent disruption of other participants).
feasibility study of using fecal microbiota transplants in anorexia nervosa

Conditions: Anorexia Nervosa; Microbiome Dysbiosis

Summary: the investigators hypothesize that prolonged undernutrition in anorexia nervosa alters the microbiome to a different steady-state (dysbiotic) composition that sustains the disease, even after returning to normal diet. the investigators propose that transplanting a fully ecologically functioning gm from a healthy donor, through a fmt, can reboot the gut-brain-axis, ameliorate symptoms and improve clinical outcomes. to approach this, in the challenging an patient group, the investigators want to conduct a fmt feasibility/pilot study.

anorexia nervosa (an) still carries the highest fatality rate of any psychiatric disease, and less than half of the patients recover, completely refractory to any treatment. the etiology remains unknown and evidence for treatment is lacking. we have an established collaboration bridging several disciplines and people in medicine, bioinformatics and biology with a focus on the pathological role of gut microbiome in the psychiatric disorder anorexia nervosa. the gm in healthy people has been shown to affect weight gain, appetite and behavior through the gut-brain axis. we hypothesize that prolonged undernutrition in an alters the microbiome to a different steady-state (dysbiotic) composition that sustains the disease, even after returning to normal diet. an patients enter voluntarily into programs of therapeutic weight gain and reintroduction to normal food intake. the investigators propose that transplanting a fully ecologically functioning gm from a healthy donor, through a fmt, can reboot the gut-brain-axis, ameliorate symptoms and improve clinical outcomes. to approach this, in the challenging an patient group, we want to conduct a fmt feasibility/pilot study. the investigators want approach the fmt intervention, with 20 an patients in sequence before any attempt at more complex blinded /placebo clinical trials. the investigators will collect gm samples and clinical data from these patients and describe the altered composition and diversity of the an-gm and how it changes with fmt. ultimately, the investigators aim to provide evidence that gm modulation with fmt can ameliorateclinical outcomes of an. the investigators will investigate the feasibility of using fmt in supportive treatment of an and by identifying specific bacterial and viral changes with fmt, we will lay the groundwork for randomized placebo-controlledstudies, to develop new gm interventions to complement current treatment of an.

Eligibility criteria:
inclusion: women referred to the participating specialized centers or by advertising who fulfill the of a diagnosis of anorexia nervosa according to the criteria as specified in the diagnostic and statistical manual of mental disorders(dsm) version 5. exclusion: age \<18 years. known ongoing abuse of laxatives. antibiotic treatment within the last three months. probiotics within the last month inflammatory bowel disease, colorectal cancer or other known chronic bowel disorder
quantitative analysis of functional ct imaging of coronary atherosclerosis

Conditions: Coronary Artery Disease

Summary: the purpose of this prospective observational study is to evaluate the diagnostic and prognostic performance of a "one-stop" comprehensive coronary artery anatomy and function assessment for cad.

coronary ct angiography (ccta) has become a reliable diagnostic technique to evaluate coronary artery disease (cad) with high sensitivity and a negative predictive value. however, ccta provides only anatomic information and tends to overestimate stenosis severity and is limited in its ability to diagnose myocardial ischemia. undertaking additional ct myocardial perfusion imaging(ct-mpi) and ct-ffr improves specificity and positive predictive value, reducing unnecessary invasive coronary angiography. the purpose of this prospective observational study is to evaluate the diagnostic and prognostic performance of a "one-stop" comprehensive coronary artery anatomy and function assessment for cad. spect myocardial perfusion imaging (spect-mpi)and invasively measured fractional flow reserve (ffr) will serve as the reference standard.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. understand the purpose of the trial, voluntarily participate in this study, and have signed an informed consent form. 3. patients with known or suspected cad exclusion criteria: 1. patients with acute coronary syndrome. 2. severe cardiac dysfunction (lvef ≤ 0.3). 3. cardiomyopathy with non-coronary causes such as hypertrophic cardiomyopathy, dilated cardiomyopathy, alcoholic cardiomyopathy, and myocardial amyloidosis. 4. severe cardiac valve disease with more than moderate valvular regurgitation and/or valvular stenosis. 5. severe hepatic and renal dysfunction (alt ≥ 3 upper limit of normal, cr\> 134μ/mol/l (2mg/dl) or estimated glomerular filtration rate\<45ml/min/1.73m2). 6. severe arrhythmias (persistent atrial fibrillation, second-degree or third-degree atrioventricular block, etc.) 7. malignancy or other pathophysiological conditions with an expected survival of less than 1 year 8. allergic to the drug components involved in this study and those who are intolerant to loading tests 9. pregnant or lactating women. 10. mental disorders. 11. failure to sign the informed consent form. 12. other conditions that are incompatible with the clinical study.

Keywords: ct myocardial perfusion imaging spect myocardial perfusion imaging
a study of ne3107 in early parkinson's

Conditions: Parkinsons Disease (PD)

Summary: the goal of this clinical trial is to learn if bezisterim can treat movement symptoms of parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any form of levodopa or drug with similar activity. the main questions it aims to answer are: * will bezisterim decrease movement symptoms of parkinson's disease? * what medical problems do participants have when taking bezisterim? researchers will compare the effects of bezisterim treatment to placebo (a look-alike substance that contains no drug) to see if bezisterim works to treat movement symptoms of parkinson's disease. participants will * have a physical examination that includes an electrocardiogram * take drug or placebo twice daily for four months * visit a clinical site or receive an at home visit seven times over the course of five months


Eligibility criteria:
inclusion criteria: * 45 years to 80 years of age * diagnosed with idiopathic parkinson's disease (pd) within 18 months * nearing the need for symptomatic therapy * agree to use birth control measures * provide voluntary consent * willing to allow blood collection for dna methylation analysis * pass all screening tests and procedures exclusion criteria: * has taken levodopa or another similar drug for the motor symptoms of pd * a known or strongly suspected familial cause for pd diagnosis * major mental health or physical illness * medical history of major mental or physical illness

Keywords: treatment naïve parkinson's early parkinson's